NCT06299124View on ClinicalTrials.gov

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions

Breast CancerAdvanced Solid Tumor

Interventions

DRUG

RGT-419B

RGT-419B will be administered orally

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Regor Pharmaceuticals Inc.

INDUSTRY